← Back to headlines
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Novo Nordisk's shares experienced a significant drop after its new obesity drug failed to outperform Eli Lilly's Zepbound in clinical trials.
23 Feb, 16:44 — 23 Feb, 16:44
Sources
Showing 1 of 1 sources
